XML 59 R47.htm IDEA: XBRL DOCUMENT v3.25.2
GQ BIO THERAPEUTICS ACQUISITION - Schedule of Indicates the Consideration Transferred to Effect the Acquisition of GQ Bio (Details) - USD ($)
$ in Thousands
 4 Months Ended
Jun. 30, 2025
Feb. 27, 2025
Dec. 31, 2024
Dec. 31, 2023
LIABILITIES ASSUMED        
Goodwill $ 20,300   $ 0 $ 163,243
GQ Bio Acquisition        
ASSETS ACQUIRED        
Cash and cash equivalents 1,884 $ 1,884    
Accounts receivable 900 900    
Prepaid expenses and other assets 503 120    
Fixed assets 364 364    
Right-of-use assets 1,374 1,374    
In-process research and development (IPR&D) 22,500 22,500    
Other noncurrent assets 56 56    
Total assets 27,581 27,198    
LIABILITIES ASSUMED        
Accounts payable 998 1,037    
Accrued expenses 282 91    
Lease liabilities 1,374 1,374    
Deferred tax liability 4,086 6,750    
Other liabilities 49 49    
Total liabilities 6,789 9,301    
Total identifiable net assets acquired 20,792 17,897    
Goodwill 18,099 20,763    
Total fair value of the GQ Bio Acquisition 38,891 $ 38,660    
Measurement Period Adjustments        
Cash and cash equivalents 0      
Accounts receivable 0      
Prepaid expenses and other assets 383      
Fixed assets 0      
Right-of-use assets 0      
In-process research and development (IPR&D) 0      
Other noncurrent assets 0      
Total assets 383      
Accounts payable (39)      
Accrued expenses 191      
Lease liabilities 0      
Deferred tax liability (2,664)      
Other liabilities 0      
Total liabilities (2,512)      
Total identifiable net assets acquired 2,895      
Goodwill (2,664)      
Total fair value of the GQ Bio Acquisition $ 231